DNMT3A and acute myeloid leukemia: Given the aggressive nature of DNMT3A/FLT3ITD AML, we administered an initial dose of 25 μg/mouse for the first three doses, followed by an increased dose of 50 μg/mouse for the remaining seven doses (Supplementary Fig. 27A).